ABCG2 and non-small cell lung carcinoma: In a previous study assessing the impact of the BCRP transporter on the clinical outcomes of advanced non-small cell lung cancer in a regimen incorporating cisplatin, in comparison to the BCRP-negative patients, the response rate to the treatment was lower in BCRP-positive tumors (P = 0.08).